PT - JOURNAL ARTICLE AU - Ramuta, Mitchell D. AU - Newman, Christina M. AU - Brakefield, Savannah F. AU - Stauss, Miranda R. AU - Wiseman, Roger W. AU - Kita-Yarbro, Amanda AU - O’Connor, Eli J. AU - Dahal, Neeti AU - Lim, Ailam AU - Poulsen, Keith P. AU - Safdar, Nasia AU - Marx, John A. AU - Accola, Molly A. AU - Rehrauer, William M. AU - Zimmer, Julia A. AU - Khubbar, Manjeet AU - Beversdorf, Lucas J. AU - Boehm, Emma C. AU - Castañeda, David AU - Rushford, Clayton AU - Gregory, Devon A. AU - Yao, Joseph D. AU - Bhattacharyya, Sanjib AU - Johnson, Marc C. AU - Aliota, Matthew T. AU - Friedrich, Thomas C. AU - O’Connor, David H. AU - O’Connor, Shelby L. TI - SARS-CoV-2 and other respiratory pathogens are detected in continuous air samples from congregate settings AID - 10.1101/2022.03.29.22272716 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.29.22272716 4099 - http://medrxiv.org/content/early/2022/03/30/2022.03.29.22272716.short 4100 - http://medrxiv.org/content/early/2022/03/30/2022.03.29.22272716.full AB - Two years after the emergence of SARS-CoV-2, there is still a need for better ways to assess the risk of transmission in congregate spaces. We deployed active air samplers to monitor the presence of SARS-CoV-2 in real-world settings across communities in the Upper Midwestern states of Wisconsin and Minnesota. Over 29 weeks, we collected 527 air samples from 15 congregate settings and detected 106 SARS-CoV-2 positive samples, demonstrating SARS-CoV-2 can be detected in air collected from daily and weekly sampling intervals. We expanded the utility of air surveillance to test for 40 other respiratory pathogens. Surveillance data revealed differences in timing and location of SARS-CoV-2 and influenza A virus detection in the community. In addition, we obtained SARS-CoV-2 genome sequences from air samples to identify variant lineages. Collectively, this shows air surveillance is a scalable, cost-effective, and high throughput alternative to individual testing for detecting respiratory pathogens in congregate settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible by financial support through Rockefeller Regional Accelerator for Genomic Surveillance (133 AAJ4558), Wisconsin Department of Health Services Epidemiology and Laboratory Capacity funds (144 AAJ8216), and National Institutes of Health grant (U01DA053893). We would like to thank Thermo Fisher Scientific, Inc. for donating 4 of the AerosolSense samplers used in the data described in this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the University of Wisconsin-Madison Health Sciences waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors